Disease-free survival is significantly longer with adjuvant pembrolizumab than observation among patients with high-risk ...

For patients with limited-stage small cell lung cancer, adjuvant therapy with durvalumab leads to significantly longer ...

Discover the results from the phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study, presented at ESMO 2024, Barcelona, Spain ...

No Premier League manager departures so far this season; only 42 per cent of teams retain top-flight status after axing ...

The following is a summary of “Impact of Donor−Recipient BMI Ratio on Survival Outcomes of Heart Transplant Recipients: A ...

AI stocks like Nvidia have outperformed the market. Click here to learn strategies to manage risk and enhance portfolio ...

Researchers conducted a single-center cohort study of more than 47,000 patients diagnosed with CRC from January 1, 1973, to ...

Immunotherapy, which works by enabling the body's immune system to recognize and destroy cancer cells improves long-term ...

Researchers developed a pan-immune-inflammation–based nomogram to accurately predict overall survival (OS) and ...

Patients with locally advanced cervical cancer were randomized to receive either pembrolizumab or placebo in combination with ...

The following is a summary of “Final, 10-Year outcomes with Nivolumab plus Ipilimumab in advanced melanoma,” published in the September 2024 issue of Dermatology by Wolchok et al. Researchers ...

Notably, patients benefited from pembrolizumab regardless of whether they achieved a pathologic complete response (pCR), ...